We've found
33,560
archived clinical trials in
Neurology
We've found
33,560
archived clinical trials in
Neurology
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants
Updated: 9/22/2017
In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight (ELBW) Infants
Status: Enrolling
Updated: 9/22/2017
Click here to add this to my saved trials
Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Updated: 9/25/2017
Safety and Efficacy of Cervical Sympathetic Block in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage - Pilot Study
Status: Enrolling
Updated: 9/25/2017
Safety Study of Cervical Sympathetic Block for Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Updated: 9/25/2017
Safety and Efficacy of Cervical Sympathetic Block in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage - Pilot Study
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Safe Administration of Flu Vaccine to Egg Allergic Children
Updated: 9/25/2017
Multi-Centered, Randomized, Placebo-Controlled Trial of the Safety of Influenza Vaccine in Egg Allergic Children With a History of Anaphylaxis or Severe Allergy to Egg
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Phase I/II Single Center, Open-Label Study Examining Image Result for Pharmacokinetics of 2 Modified-Release Formulations of MPH in Adolescent/Pediatric With ADHD
Updated: 9/25/2017
Phase I/II Single Center/Treatment Open-Label Adaptive Trial Examining the PK of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 9/25/2017
Phase I/II Single Center, Open-Label Study Examining Image Result for Pharmacokinetics of 2 Modified-Release Formulations of MPH in Adolescent/Pediatric With ADHD
Updated: 9/25/2017
Phase I/II Single Center/Treatment Open-Label Adaptive Trial Examining the PK of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Updated: 9/25/2017
A Long Term, Open-Label, Safety Study of Eszopiclone in Children (6 to 11 Years) and Adolescents (12 to 17 Years) With Attention Deficit/Hyperactivity Disorder Associated Insomnia
Status: Enrolling
Updated: 9/25/2017
Click here to add this to my saved trials